Annual Accounts Payable
$446.00 K
-$2.44 M-84.52%
December 31, 2023
Summary
- As of February 24, 2025, AVTX annual accounts payable is $446.00 thousand, with the most recent change of -$2.44 million (-84.52%) on December 31, 2023.
- During the last 3 years, AVTX annual accounts payable has fallen by -$2.13 million (-82.67%).
- AVTX annual accounts payable is now -86.76% below its all-time high of $3.37 million, reached on December 31, 2021.
Performance
AVTX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$1.81 M
+$1.16 M+176.91%
September 30, 2024
Summary
- As of February 24, 2025, AVTX quarterly accounts payable is $1.81 million, with the most recent change of +$1.16 million (+176.91%) on September 30, 2024.
- Over the past year, AVTX quarterly accounts payable has stayed the same.
- AVTX quarterly accounts payable is now -84.80% below its all-time high of $11.91 million, reached on March 31, 2021.
Performance
AVTX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
AVTX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -84.5% | 0.0% |
| 3 y3 years | -82.7% | 0.0% |
| 5 y5 years | -69.2% | 0.0% |
AVTX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -86.8% | at low | -67.5% | +306.1% |
| 5 y | 5-year | -86.8% | at low | -84.8% | +306.1% |
| alltime | all time | -86.8% | at low | -84.8% | +479.5% |
Avalo Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.81 M(+176.9%) |
| Jun 2024 | - | $654.00 K(-28.6%) |
| Mar 2024 | - | $916.00 K(+105.4%) |
| Dec 2023 | $446.00 K(-84.5%) | $446.00 K(-43.5%) |
| Sep 2023 | - | $789.00 K(+5.1%) |
| Jun 2023 | - | $751.00 K(-86.5%) |
| Mar 2023 | - | $5.57 M(+93.1%) |
| Dec 2022 | $2.88 M(-14.5%) | $2.88 M(+99.2%) |
| Sep 2022 | - | $1.45 M(-33.1%) |
| Jun 2022 | - | $2.16 M(-42.4%) |
| Mar 2022 | - | $3.76 M(+11.5%) |
| Dec 2021 | $3.37 M(+30.9%) | $3.37 M(-5.6%) |
| Sep 2021 | - | $3.57 M(-10.0%) |
| Jun 2021 | - | $3.96 M(-66.7%) |
| Mar 2021 | - | $11.91 M(+362.8%) |
| Dec 2020 | $2.57 M(+23.9%) | $2.57 M(+33.6%) |
| Sep 2020 | - | $1.93 M(-24.7%) |
| Jun 2020 | - | $2.56 M(-6.2%) |
| Mar 2020 | - | $2.73 M(+31.2%) |
| Dec 2019 | $2.08 M | $2.08 M(+151.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $826.50 K(-42.8%) |
| Jun 2019 | - | $1.45 M(+15.7%) |
| Mar 2019 | - | $1.25 M(-13.6%) |
| Dec 2018 | $1.45 M(+11.3%) | $1.45 M(-5.8%) |
| Sep 2018 | - | $1.54 M(-47.8%) |
| Jun 2018 | - | $2.94 M(-7.1%) |
| Mar 2018 | - | $3.17 M(+143.7%) |
| Dec 2017 | $1.30 M(+28.6%) | $1.30 M(+315.7%) |
| Sep 2017 | - | $312.50 K(-4.5%) |
| Jun 2017 | - | $327.30 K(-45.1%) |
| Mar 2017 | - | $595.90 K(-41.0%) |
| Dec 2016 | $1.01 M(+49.0%) | $1.01 M(+24.8%) |
| Sep 2016 | - | $809.20 K(+7.0%) |
| Jun 2016 | - | $756.50 K(+28.0%) |
| Mar 2016 | - | $591.00 K(-12.8%) |
| Dec 2015 | $678.10 K(-27.2%) | $678.10 K(-65.3%) |
| Sep 2015 | - | $1.95 M(+56.6%) |
| Jun 2015 | - | $1.25 M(+72.6%) |
| Mar 2015 | - | $722.00 K(-22.5%) |
| Dec 2014 | $931.10 K(-43.2%) | $931.10 K |
| Dec 2013 | $1.64 M | - |
FAQ
- What is Avalo Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Avalo Therapeutics?
- What is Avalo Therapeutics annual accounts payable year-on-year change?
- What is Avalo Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly accounts payable year-on-year change?
What is Avalo Therapeutics annual accounts payable?
The current annual accounts payable of AVTX is $446.00 K
What is the all time high annual accounts payable for Avalo Therapeutics?
Avalo Therapeutics all-time high annual accounts payable is $3.37 M
What is Avalo Therapeutics annual accounts payable year-on-year change?
Over the past year, AVTX annual accounts payable has changed by -$2.44 M (-84.52%)
What is Avalo Therapeutics quarterly accounts payable?
The current quarterly accounts payable of AVTX is $1.81 M
What is the all time high quarterly accounts payable for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly accounts payable is $11.91 M
What is Avalo Therapeutics quarterly accounts payable year-on-year change?
Over the past year, AVTX quarterly accounts payable has changed by $0.00 (0.00%)